BLRX BioLineRx Ltd

USD 1.1100 0.08 (+7.77%)
Icon

BioLineRx Ltd (BLRX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.11

+0.08 (+7.77)%

USD 0.10B

0.35M

N/A

N/A

Icon

BLRX

BioLineRx Ltd (USD)
COMMON STOCK | NSD
USD 1.1100
0.08 (+7.77%)
At close: 04:00PM EDT
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.10B

N/A

USD 1.11

BioLineRx Ltd (BLRX) Stock Forecast

N/A

Based on the BioLineRx Ltd stock forecast from 0 analysts, the average analyst target price for BioLineRx Ltd is not available over the next 12 months. BioLineRx Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioLineRx Ltd is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, BioLineRx Ltd’s stock price was USD 1.11. BioLineRx Ltd’s stock price has changed by -6.72% over the past week, -9.76% over the past month and +35.37% over the last year.

No recent analyst target price found for BioLineRx Ltd
No recent average analyst rating found for BioLineRx Ltd

Company Overview BioLineRx Ltd

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment ...Read More

https://www.biolinerx.com

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

49

December

USD

USA

Adjusted Closing Price for BioLineRx Ltd (BLRX)

Loading...

Unadjusted Closing Price for BioLineRx Ltd (BLRX)

Loading...

Share Trading Volume for BioLineRx Ltd Shares

Loading...

Compare Performance of BioLineRx Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLRX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BioLineRx Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing BLRX

Symbol Name BLRX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BioLineRx Ltd (BLRX) Stock

Stock Target Advisor's fundamental analysis for BioLineRx Ltd's stock is Bearish.

Unfortunately we do not have enough data on BLRX's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BLRX's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BLRX's stock to indicate if its overvalued.

The last closing price of BLRX's stock was USD 1.11.

The most recent market capitalization for BLRX is USD 0.10B.

Unfortunately we do not have enough analyst data on BLRX's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains BioLineRx Ltd's stock.

As per our most recent records BioLineRx Ltd has 49 Employees.

BioLineRx Ltd's registered address is Modi?in Technology Park, Hevel Modi'in, Israel, 7177871. You can get more information about it from BioLineRx Ltd's website at https://www.biolinerx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...